Clicky

Oncosil Medical Ltd  (OSL)

Description: OncoSil Medical Limited is a late-stage medical device company, which is focused on localized treatments for patients with pancreatic and liver cancer. The Company is engaged in the development of its lead product candidate, the OncoSil localized radiation therapy, for the treatment of pancreatic cancer. The Company's lead product, OncoSil, is a brachytherapy device that emits beta radiation and is implanted directly inside the cancerous tumor. OncoSil is a silicon and phosphorus (p32) beta emitter, able to be implanted intra-tumorally via endoscopic ultrasonography in localized solid tumors of patients with pancreatic cancer. The Company focuses on an application for Conformite Europeene (CE) Mark to enable commercial sales of OncoSil in the European Union and an application for an Investigational Device Exemption (IDE) from the United States Food and Drug Administration (FDA) to enable commencement of the United States pivotal clinical study, known as OncoPac-1.


Keywords: Medicine Cancer Cement Solid Tumors Medical Device Tumor Radiation Medical Physics Implant Radiation Therapy Pancreatic Cancer Liver Cancer Phosphorus Medical Ultrasonography Medical Ultrasound Radioactivity Brachytherapy Pivot Treatment Of Pancreatic Cancer United States Food And Drug Administration

Home Page: www.oncosil.com.au

OSL Technical Analysis

15 Blue Street
North Sydney, NSW 2060
Australia
Phone: 61 2 9223 3344


Officers

Name Title
Mr. Nigel Lange CEO, MD & Director
Mr. Karl David Pechmann CFO & Company Sec.
Mr. Michael Warrener Global Sales & Marketing Director
Dr. David Charles James Global Head of Manufacturing Operations
Dr. Ralph Peters Chief Medical Officer
Mr. David Turner Head of Medical Affairs

Exchange: AU

Country: AU

Currency: Australian Dollar (A$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 4.008
Price-to-Sales TTM: 46.7488
IPO Date: 2005-08-15
Fiscal Year End: June
Full Time Employees: 0
Back to stocks